# MK-1167 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mk-1167

> MK-1167, sponsored by Merck & Co., Inc. (MRK): 1 recorded catalyst.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | MK-1167 |
| Codes | MK-1167 |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | [Alzheimer Disease](https://sec-api.dev/indications/alzheimer-disease) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### June 5, 2026: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 2. Indication: Alzheimer Disease; Dementia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06721156 (A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-06-05 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06721156

## Same indication

- [[18f]pi-2620](https://sec-api.dev/pdufa/18f-pi-2620) (LNTH)
- [Dn-tnf](https://sec-api.dev/pdufa/dn-tnf) (INMB)
- [Donanemab](https://sec-api.dev/pdufa/donanemab) (LLY)
- [Igc-ad1-active](https://sec-api.dev/pdufa/igc-ad1-active) (IGC)
- [JNJ-63733657](https://sec-api.dev/pdufa/jnj-63733657) (JNJ)
- [JNJ-64042056](https://sec-api.dev/pdufa/jnj-64042056) (JNJ)
- [Karxt](https://sec-api.dev/pdufa/karxt) (BMY)
- [Mevidalen](https://sec-api.dev/pdufa/mevidalen) (LLY)
- [Primec](https://sec-api.dev/pdufa/primec) (NRSN)
- [Sabirnetug](https://sec-api.dev/pdufa/sabirnetug) (ABOS)
- [Xanomeline/trospium chloride](https://sec-api.dev/pdufa/xanomeline-trospium) (BMY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mk-1167.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MK-1167 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mk-1167

```bibtex
@misc{secapidev_pdufa_mk_1167_20261116,
  title        = {MK-1167 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mk-1167}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mk_1167_20261116","title":"MK-1167 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mk-1167","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
